ArticleBlood advances2018
CXCR5 and ICOS expression identifies a CD8 T-cell subset with T
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 37 citations in OpenAlex.
- C-X-C chemokine receptor type 5World journal of gastroenterology · 2025Trial
- Viral load-driven systemic immune exhaustion is an enabler of antibody breadth in HIV infection.bioRxiv : the preprint server for biology · 2026Article
- Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.British journal of haematology · 2026Article
- The role of CD40L-expressing CXCR5Immunologic research · 2025Article
- Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact.Cancers · 2024Article
- ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis.Journal for immunotherapy of cancer · 2024Article
- IL-27 promotes pathogenic T cells in a mouse model of Sjögren's disease.Clinical immunology (Orlando, Fla.) · 2024Article
- CTLs heterogeneity and plasticity: implications for cancer immunotherapy.Molecular cancer · 2024Review
- Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.Biology · 2023Review
- Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.Diagnostics (Basel, Switzerland) · 2022Review
- Altered levels of circulating CD8Clinical rheumatology · 2022Article
- Antibody-suppressor CXCR5American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.Cancers · 2022Review
- Biology and clinical relevance of follicular cytotoxic T cells.Frontiers in immunology · 2022Review
- Non-cytotoxic functions of CD8 T cells: "repentance of a serial killer".Frontiers in immunology · 2022Review
- CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjögren's Syndrome.Frontiers in immunology · 2022Article
- Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity.The Journal of clinical investigation · 2021Article
- The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas.Cancers · 2021Review
- CD8 follicular T cells localize throughout the follicle during germinal center reactions and maintain cytolytic and helper properties.Journal of autoimmunity · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A better characterization of T-cell subsets in the microenvironment of classical Hodgkin lymphoma (cHL) would help to develop immunotherapies. Using multicolor flow cytometry, we identified in 6 of 43 cHL tissue samples a previously unrecognized subset of CD8 T cells coexpressing CXCR5 and inducible T-cell costimulator (ICOS) molecules (CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.